Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK

Executive Summary

An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims

You may also be interested in...



Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA

Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent

Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA

Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent

Eon Wellbutrin SR Generic Launch Could Slow GSK Conversion Efforts

Eon's launch of generic bupropion extended-release (Wellbutrin SR) should allow it to grab significant market share before GlaxoSmithKline fully converts SR patients to once-daily Wellbutrin XL

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS042550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel